Form D · Biotechnology
Insys Therapeutics, Inc.
Phoenix, AZ · CIK 0001516479
Offering snapshot reported Apr 8, 2011 · SEC filing
- Reported sold
- $2.32M Offering amount: $2.32M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 28, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 8, 2011 | Initial | $2,315,006 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-158053
Source: Form D, filed Apr 8, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Babich | Director, Executive |
| Larry Dillaha | Executive |
| Patrick Fourteau | Director |
| John Kapoor | Director |
| Pierre Lapalme | Director |
| Richard Mallery | Director |
| Martin Mc Carthy | Executive |
| Steven Meyer | Director |
| Brian Tambi | Director |
| Daniel Von Hoff | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10220 South 51 St Street Suite 2
Phoenix, AZ, 85044
Phoenix, AZ, 85044